Sleep Apnea
Also known as: Obstructive sleep apnea, OSA, sleep-disordered breathing
Higher
Undiagnosed rates in Black adults — disparity in screening and treatment
Overview
Obstructive sleep apnea (OSA) is a chronic sleep disorder characterized by repeated partial or complete upper airway obstruction during sleep, causing oxygen desaturation and arousal from sleep. The apnea-hypopnea index (AHI) quantifies severity: mild is AHI 5–14 events/hour, moderate 15–29, and severe 30 or more. OSA affects an estimated 24–34% of middle-aged men and 17–28% of women, with prevalence rising with obesity, age, and other risk factors. Untreated OSA substantially elevates the risk of hypertension, heart failure, atrial fibrillation, stroke, type 2 diabetes, motor vehicle accidents from daytime sleepiness, and all-cause mortality. CPAP (continuous positive airway pressure) remains the most effective treatment for moderate-to-severe OSA.
How Sleep Apnea affects Black patients
Black adults have equal or greater OSA prevalence compared to white adults, yet they are diagnosed at substantially lower rates — a disparity documented in multiple analyses of sleep clinic referral and polysomnography data. Several mechanisms contribute: provider suspicion of OSA is lower in Black patients despite equivalent or higher symptom burden; structural access barriers reduce sleep study referrals; and oximetry-based screening (pulse oximetry) is less accurate in individuals with darker skin pigmentation, potentially masking nocturnal desaturation events that trigger referral.
Risk factors prevalent in Black communities — obesity, hypertension, type 2 diabetes — create a self-reinforcing cycle: untreated OSA worsens cardiovascular and metabolic conditions, which in turn increase OSA severity. Data from the Multi-Ethnic Study of Atherosclerosis (MESA) Sleep ancillary study showed that Black adults had more severe sleep-disordered breathing than white adults at equivalent BMI. Menopause sharply increases OSA risk in women, and Black women have earlier mean menopausal age than white women.
Symptoms
- Loud, chronic snoring (often reported by bed partner)
- Witnessed apneas — pauses in breathing during sleep
- Gasping or choking sounds at night
- Excessive daytime sleepiness (Epworth Sleepiness Scale score ≥10)
- Morning headaches, dry mouth, or sore throat
- Difficulty concentrating, memory problems, irritability
- Nocturia (waking repeatedly to urinate)
- Restless sleep, frequent nighttime awakenings
When to see a doctor
Ask your primary care provider about OSA screening if you snore regularly, have been told you stop breathing in your sleep, or experience significant daytime sleepiness — especially if you have hypertension, diabetes, obesity, or a neck circumference above 17 inches (men) or 16 inches (women). Request a referral to a sleep specialist (pulmonology or sleep medicine) if symptoms are present.
Home sleep tests (HST/HSAT) are now widely covered by insurance for uncomplicated OSA screening and do not require overnight hospital or lab stays. In-lab polysomnography is preferred when comorbidities such as heart failure, COPD, or parasomnias are present.
Screening
The USPSTF found insufficient evidence to recommend for or against OSA screening in asymptomatic adults (2017 statement). However, clinical guidelines from the American Academy of Sleep Medicine (AASM) recommend systematic screening in high-risk groups: obese individuals, those with refractory hypertension, pre-operative surgical patients, and commercial vehicle drivers. Validated screening tools include the STOP-BANG questionnaire (8 items) and the Epworth Sleepiness Scale. Black adults with any cardiovascular or metabolic comorbidity should receive proactive OSA discussion given documented diagnostic disparities.
Treatment overview
CPAP therapy, which delivers continuous positive airway pressure through a mask to prevent airway collapse, is the gold-standard treatment for moderate and severe OSA and is highly effective when used consistently (≥4 hours/night on ≥70% of nights). For CPAP-intolerant patients, BiPAP (bilevel PAP) provides distinct inspiratory and expiratory pressures and may improve tolerance. Oral appliances (mandibular advancement devices) are effective for mild-to-moderate OSA and preferred by many patients. Positional therapy (avoiding supine sleeping) helps in position-dependent OSA. The hypoglossal nerve stimulator (Inspire) is FDA-approved for moderate-to-severe OSA in patients who cannot tolerate CPAP — it electrically stimulates the tongue during sleep to maintain airway patency. Surgical upper airway procedures (uvulopalatopharyngoplasty, maxillomandibular advancement) benefit selected anatomic candidates. Weight loss of 10% or more reduces AHI by approximately 26% in obese patients. All OSA treatment reduces cardiovascular risk, improves glucose control in diabetes, and reduces accident risk from daytime sleepiness.
Questions to ask your doctor
Bring this list to your next appointment.
- Can I have a home sleep test (HST) — and is my insurance likely to cover it?
- What is my AHI, and which OSA severity category do I fall in?
- What CPAP pressure is recommended, and can I get a full-face mask (not just nasal)?
- What options exist if I cannot tolerate CPAP — BiPAP, oral appliance, Inspire?
- How does untreated OSA interact with my blood pressure and diabetes?
- Is my daytime sleepiness severe enough that I should not drive until treated?
Find a Pulmonology
Search our directory of verified Black health providers who specialize in pulmonology.
Browse Pulmonology providersMedical disclaimer
This content is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. If you are experiencing a medical emergency, call 911 or your local emergency number immediately.